Driven by passion
for innovation

A leading specialist provider of minimally invasive cardiac devices

Occlutech occluders
Occlutech interview brand
Play Video about Occlutech interview brand

Annual and Sustainability Report

OCCLUTECH ASD OCCLUDER

Rate of successful device placement at first attempt: 99,1%, according to a study.

NEWS

Occlutech announces first US patient enrolled in important FDA study.

EVENTS

Our new booth is ready to travel. Occlutech will be participating in several congresses in the next months. Take a look!

OCCLUTECH AS AN INVESTMENT

Occlutech is advancing its position with the US launch in progress and is preparing for a listing in 2023.

EVENTS

Our new booth is ready to travel. Occlutech will be participating in several congresses in the next months. Take a look!

Occlutech events

Our products

Occlutech creates products that can be implanted in a high rate of patients, avoiding surgery, while minimizing potentially fatal complications. With over 150,000 sold devices, Occlutech has a product performance track record and experience of more than 15 years.

AFR for Heart Failure

The Atrial Flow Regulator (AFR) is a transcatheter cardiac implant, designed for use in patients with heart failure (either HFpEF or HFrEF) who continue to experience worsening symptoms despite optimal medical therapy.

The AFR reduces the pressure in the left side of the heart by maintaining a controlled interatrial septal shunt between the left and right atrium. The procedure is minmally invasive and initial results show a 100% success with the device1

AFR logo
AFR occluder

OVER 150 000
OCCLUDERS IN 85 COUNTRIES

Occlutech’s products are implanted in thousands of human hearts every year. Quality and the product’s consistent performance are key to the trust of thousands of physicians who use them.

We are dedicated to perfecting physicians’ performance around the world for the benefit of their patients.

Perfecting Performance

Career

Career

We are looking for highly motivated individuals inspired by making a difference in patients’ lives to join our dynamic teams.

Press Releases

  • All
  • Staff change
  • Press Releases
  • Other Corporate Information
  • Other
  • News
  • mfn-cus-disclaimer
  • IR
  • English
  • Corporate Information
  • Corporate Action
  • 2022
  • 2021
  • 2020
  • 2019

News

Content references:
  1. https://pubmed.ncbi.nlm.nih.gov/31130524/